Evidence map›Paper›PMID 40980911›Full record

ArticleAntimicrobial agents and chemotherapy2025

Noncytotoxic polymyxin derivatives enhance antibiotic action against multidrug-resistant Gram-negative bacteria.

Danyel Ramirez, Danzel Marie Ramirez, Rajat Arora, Gilbert Arthur, Frank Schweizer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danyel RamirezDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0009-0002-0829-3242
Danzel Marie RamirezDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.
Rajat AroraDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.
Gilbert ArthurDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.
Frank SchweizerDepartment of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-8697-5519

Funding

NSERC 2018-06047UMGF
6 · The paper itself

Abstract

The widespread emergence of multidrug-resistant (MDR) Gram-negative bacteria prompted the reintroduction of polymyxins in the clinic despite their adverse effects. Ongoing research is primarily focused on the development of non-nephrotoxic and -neurotoxic polymyxins as not only standalone agents but also as potentiators that enhance the activity of a partner antibiotic. Safer derivatives of polymyxin B

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialGram-Negative BacteriaPolymyxinsAcinetobacter baumanniiDrug SynergismEnterobacter cloacaeEscherichia coliHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsPolymyxin BPseudomonas aeruginosaRifampinAnti-Bacterial AgentsPolymyxin BPolymyxinsRifampinantibiotic adjuvantantibiotic potentiatorGram-negative bacteriapolymyxin

Identifiers

PMID40980911
PMCPMC12587545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.